Review
======

Over the past 20 years, cancer free survival has improved for many individuals with prostate, renal, breast, and hematologic malignancies. Unfortunately, an unintended consequence of many of the therapies that have contributed to this improvement in cancer-free survival has been the increasingly recognized evolution of cardiovascular (CV) events \[[@B1]-[@B12]\]. Several recently published research studies provide insight into possible etiologies of these events. Result from studies involving the Centers for Medicare-Medicaid Services (CMS) and Health Maintenance Organization (HMO) databases within the United States indicate an increased prevalence of billing codes for heart failure, myocardial infarction (MI), and cardiac arrhythmias in patients treated for cancer \[[@B1]-[@B12]\]. Also in these studies, there is an increased frequency of codes related to the administration of chemotherapy for cancer that precedes the onset of codes for CV disease and events. The fact that chemotherapy codes precede CV event codes in cancer patients implies a temporal relationship between the administration of cancer treatment and the subsequent occurrence of CV events.

Importantly, the number of cancer survivors who experience subsequent CV events is large. In the US alone, there are now over 13 million cancer survivors, and for breast cancer alone, it is estimated that over \$800 million will be spent annually providing CV care for these women \[[@B2]-[@B4]\]. As a result, there is an emerging need to develop accurate, cost-effective methods to identify those individuals treated for cancer at increased risk of CV events.

Cardiovascular magnetic resonance (CMR) with its inherent ability to characterize myocardial tissue and identify both cardiac and vascular dysfunction has the potential to identify both subclinical and early clinical CV injury before the development of an overt catastrophic event such as a MI, stroke or premature cardiac death. Early identification of subclinical CV injury provides an opportunity for the implementation of primary prevention strategies to prevent these untoward CV events. By reducing CV related events in those treated for cancer, the opportunity exists to improve overall cancer survivorship.

In this article, we review the data indicating an increased incidence of CV events in cancer survivors, the underlying mechanisms of these events, and the potential of CMR to provide early diagnosis of subclinical CV injury related to the administration of therapy for cancer, and therefore to guide therapeutic interventions to reduce the overall CV related mortality and morbidity associated with therapy for cancer.

Cardiovascular injury and disease after cancer treatment
--------------------------------------------------------

The 5-year survival rate for patients with breast cancer or hematologic malignancies has increased from an average of 53% in 2007, to upwards of 85% in 2012 \[[@B13],[@B14]\]. While encouraging, this positive trend in improved cancer-related mortality is tempered by an emerging increase in CV disease, morbidity, and mortality \[[@B8]\]. The reasons for this increase in CV related events are uncertain; however, the results from several studies suggest that this emergence may be related to the therapies utilized to treat the cancer. Several therapeutic interventions including the administration of chemotherapy \[[@B15]\], immunotherapy \[[@B16]\], hormone deprivation \[[@B17]\] and radiation related therapy \[[@B18],[@B19]\] have been associated with CV related increases in morbidity or mortality. The injuries and abnormalities associated with cancer treatment can be highly variable and depend on the type of cancer treatment received. In Table [1](#T1){ref-type="table"}, a review of the agents previously associated with CV injury is provided. Below, we briefly discuss three categories of agents associated with CV events.

###### 

Cancer therapeutic agents, risk factors, mechanisms, and manifestations of cardiotoxicity

  **Therapeutic agent**                 **Therapeutic indications**                                                                 **Risk factors**                        **Mechanisms**                                                                   **Manifestations of cardiotoxicity**
  ------------------------------------- ------------------------------------------------------------------------------------------- --------------------------------------- -------------------------------------------------------------------------------- --------------------------------------
  **Anthracyclines**                                                                                                                                                                                                                                         
  Doxorubicin                           Breast cancer                                                                               Concurrent chemotherapy                 Cellular apoptosis induction                                                     *Early*
  Daunorubicin                          Gastric                                                                                     Dosing schedules                        ETC. uncoupling                                                                  CHF/LV dysfunction
  Epirubicin                            Leukemias                                                                                   Elderly                                 Iron complexation                                                                Myocardial ischemia/infarction
  Idarubicin                            Lung cancer                                                                                 Women                                   Lipid peroxidation of myocyte                                                    Pericarditis/myocarditis
                                        Lymphomas                                                                                   Prior radiation                         membranes                                                                        QT prolongation
  Ovarian                               IV administration                                                                           Nuclear DNA damage                      ST-T wave abnormalities                                                          
  Sarcomas                              Underlying CV disease                                                                       ROS formation                           *Late*                                                                           
  Cardiomyopathy                                                                                                                                                                                                                                             
  CHF/LV dysfunction                                                                                                                                                                                                                                         
  **Anthraquinolones**                                                                                                                                                                                                                                       
  Mitoxantrone                          AML                                                                                         Unknown                                 ROS formation                                                                    Arrhythmias
  CHF                                                                                                                                                                                                                                                        
  Breast cancer                         Myocardial ischemia/infarction                                                                                                                                                                                       
  NHL                                                                                                                                                                                                                                                        
  **Antimetabolites**                                                                                                                                                                                                                                        
  5-Fluorouracil                        Breast cancer                                                                               Underlying CV disease                   Endothelial cell damage                                                          Arrhythmias
  Colorectal cancer                                                                                                                 Vasospasm                               CHF                                                                              
  Pancreatic cancer                                                                                                                                                         Myocardial ischemia/infarction                                                   
  **Antimicrotubules**                                                                                                                                                                                                                                       
  Paclitaxel                            Breast cancer                                                                               Unknown                                 Hypersensitivity reaction                                                        Bradyarrhythmias
  CHF                                                                                                                                                                                                                                                        
  Kaposi's sarcoma                      Hypotension                                                                                                                                                                                                          
  Myocardial ischemia/infarction                                                                                                                                                                                                                             
  Lung cancer                                                                                                                                                                                                                                                
  Ovarian cancer                                                                                                                                                                                                                                             
  Vinca alkaloids                       Leukemias                                                                                   Unknown                                 Possible vasospasm                                                               Autonomic neuropathy
  Vinblastine                           Lymphomas                                                                                   Hypotension                                                                                                              
  Vincristine                           Nephroblastoma                                                                              Myocardial ischemia/infarction                                                                                           
  Raynaud's phenomenon                                                                                                                                                                                                                                       
  **Alkylating agents**                                                                                                                                                                                                                                      
  Busulfan                              CML                                                                                         Unknown                                 Unknown                                                                          Arrhythmias
  Pericardial effusion                                                                                                                                                                                                                                       
  HTN                                                                                                                                                                                                                                                        
  Pulmonary fibrosis                                                                                                                                                                                                                                         
  Cisplatin                             Germ cell tumors                                                                            Elderly                                 Coronary artery fibrosis                                                         *Early*
  Lung cancer                           Prior mediastinal irradiation                                                               Hypokalemia                             CHF                                                                              
  Lymphomas                             Use for metastatic testicular                                                               Hypomagnesaemia                         Myocardial ischemia/infarction                                                   
  Ovarian cancer                        cancer                                                                                                                              *Late*                                                                           
  Sarcomas                              Use with cyclophosphamide                                                                   Arrhythmias                                                                                                              
  HTN                                                                                                                                                                                                                                                        
  LVH                                                                                                                                                                                                                                                        
  Myocardial ischemia/infarction                                                                                                                                                                                                                             
  Cyclophosphamide                      Leukemias                                                                                   High dose regimens                      Endothelial capillary damage                                                     CHF/LV dysfunction
  Lymphomas                             Prior mediastinal irradiation                                                               Hemorrhagic myocardial necrosis                                                                                          
  Various solid tumors                  Prior anthracyclines                                                                        Hemorrhagic pericarditis                                                                                                 
  LVH                                                                                                                                                                                                                                                        
  Ifosfamide                            Lymphomas                                                                                   High dose regimens                      Myocardial fiber fragmentation                                                   Arrhythmias
  Various solid tumors                  Use for lymphomas                                                                           CHF                                                                                                                      
  **Biological agents**                                                                                                                                                                                                                                      
  Interferon-α                          Leukemias                                                                                                                           Unknown                                                                          *Early*
  Lymphomas                             Arrhythmias                                                                                                                                                                                                          
  Melanoma                              Hypertension                                                                                                                                                                                                         
  Various solid tumors                  *Late*                                                                                                                                                                                                               
  Cardiomyopathy                                                                                                                                                                                                                                             
  Interleukin-2                         Melanoma                                                                                                                            Unknown                                                                          *Early*
  RCC                                   Hypotension (capillary leak syndrome)                                                                                                                                                                                
  Myocarditis                                                                                                                                                                                                                                                
  Thrombotic events                                                                                                                                                                                                                                          
  Ventricular arrhythmias                                                                                                                                                                                                                                    
  *Late*                                                                                                                                                                                                                                                     
  Dilated Cardiomyopathy                                                                                                                                                                                                                                     
  **Hormone-modifying therapy**                                                                                                                                                                                                                              
  Androgen-deprivation therapy          Prostate cancer                                                                             Men over 65                             Development of metabolic                                                         CAD
  Underlying CV disease                 syndrome                                                                                    CHF/LV dysfunction                                                                                                       
  Dyslipidemia                          Myocardial ischemia/infarction                                                                                                                                                                                       
  Insulin resistance                    QT prolongation                                                                                                                                                                                                      
  Obesity                               SCD                                                                                                                                                                                                                  
  Aromatase Inhibitors                  Breast cancers                                                                              Unknown                                 Dyslipidemia                                                                     CAD
  Estrogen receptor (+)                                                                                                                                                     CHF/LV dysfunction                                                               
  Myocardial ischemia/infarction                                                                                                                                                                                                                             
  **Miscellaneous**                                                                                                                                                                                                                                          
  All-trans retinoic acid (Tretinoin)   APL                                                                                         Unknown                                 Unknown                                                                          Arrhythmias
  CHF                                                                                                                                                                                                                                                        
  Hypotension                                                                                                                                                                                                                                                
  Myocardial ischemia/infarction                                                                                                                                                                                                                             
  Pericardial effusions                                                                                                                                                                                                                                      
  Arsenic trioxide                      AML                                                                                         Unknown                                 Hypomagnesaemia                                                                  Arrhythmias with QT prolongation
  Pericardial effusion                                                                                                                                                                                                                                       
  Pentostatin                           Hairy cell leukemia                                                                         Use with cyclophosphamide               Unknown                                                                          Arrhythmias including A-V block
  CHF                                                                                                                                                                                                                                                        
  Myocardial ischemia/infarction                                                                                                                                                                                                                             
  **Radiation therapy**                                                                                                                                                                                                                                      
                                        Various malignancies                                                                        Prior high doses of radiation           Fibrosis caused by inflammatory                                                  *Early*
  Underlying CV disease                 changes                                                                                     Pericarditis/Pericardial effusion                                                                                        
  Use with anthracyclines               ROS formation                                                                               *Late*                                                                                                                   
  CAD                                                                                                                                                                                                                                                        
  CHF                                                                                                                                                                                                                                                        
  Conduction abnormalities                                                                                                                                                                                                                                   
  Constrictive pericarditis                                                                                                                                                                                                                                  
  Restroctive cardiomyopathy                                                                                                                                                                                                                                 
  Valvular defects                                                                                                                                                                                                                                           
  **Tyrosine-kinase inhibitors**                                                                                                                                                                                                                             
  Bevacizumab                           Colorectal cancer                                                                           Use with anthracyclines                 Monoclonal antibody against VEGF                                                 Arterial and venous thromboembolism
  HER-2 (−) breast cancer                                                                                                           Possible decrease in nitric oxide and   CHF                                                                              
  Lung cancer                                                                                                                       prostaglandin production                HTN                                                                              
  Imatinib                              GIST                                                                                        Use with anthracyclines                 Unclear, but may induce apoptosis in cardiomyocytes                              CHF/LV dysfunction
  Leukemias                             Pericardial effusion                                                                                                                                                                                                 
  Lapatinib                             HER-2 (+) breast cancer                                                                     Use with anthracyclines                 Inhibits HER-2 and EGFR                                                          LV dysfunction
  QT prolongation                                                                                                                                                                                                                                            
  Sorafenib                             HCC                                                                                         Use with anthracyclines                 Unclear, but may induce apoptosis in cardiomyocytes, or inhibit VEGF and RAF-1   CHF/LV dysfunction
  RCC                                   HTN                                                                                                                                                                                                                  
  Myocardial ischemia/infarction                                                                                                                                                                                                                             
  Thromboembolism                                                                                                                                                                                                                                            
  CHF/LV dysfunction                                                                                                                                                                                                                                         
  Sunitinib                             GIST                                                                                        Use with anthracyclines                 Unclear, but may induce apoptosis in cardiomyocytes and inhibit VEGF             HTN
  RCC                                   Thrombotic events                                                                                                                                                                                                    
  Trastuzumab                           HER-2 (+) breast cancer                                                                     Elderly                                 Defects in HER-2 signaling associated with cardiac contractility                 *Early*
  Prior mediastinal irradiation         CHF                                                                                                                                                                                                                  
  Underlying CV disease                 Immune-mediated destruction of cardiomyoytes caused by selective binding to HER-2 protein   LV dysfunction                                                                                                           
  Use with anthracyclines               *Late*                                                                                                                                                                                                               
                                                                                                                                                                                                                                                             Cardiomyopathy

*AML* acute myeloid leukemia, *APL* acute promyelocytic leukemia, *CAD* coronary artery disease, *CHF* congestive heart failure, *CML* chronic myeloid leukemia, *CV* cardiovascular, *EGFR* epidermal growth factor receptor, *ETC*. electron transport chain, *GIST* gastrointestinal stromal tumor, *HCC* haptocellular carcinoma, *HER* human epidermal growth factor receptor 2, *HTN* hypertension, *LV* left ventricle, *LVH* left ventricular hypertrophy, *NHL* non-Hodgkin's lymphoma, *RCC* renal cell carcinoma, *ROS* reactive oxygen species, *SCD* sudden cardiac death, *VEGF* vascular endothelial growth factor.

### Myocellular injury due to anthracycline chemotherapy

In children or adults treated for a hematologic malignancy or women treated for breast cancer, the administration of anthracyclines has been associated with left ventricular (LV) dysfunction and heart failure \[[@B9],[@B20]\]. In the Childhood Cancer Survivor Study (CCSS) cohort, which includes children and young adults \<21 years of age who received chemotherapy beginning in 1994, childhood cancer survivors experienced a relative risk (RR) of 15.1 (95% confidence interval \[CI\] 4.8-47.9) of developing congestive heart failure (CHF) when compared to their siblings without cancer or receipt of chemotherapy \[[@B20]\]. In a separate study of 31,748 women diagnosed with breast cancer, anthracycline chemotherapy was associated with the development of cardiomyopathy (hazard ratio \[HR\] 2.48, 95% CI 2.1 -2.93) and CHF (HR 1.38, 95% CI 1.25-1.52) \[[@B21]\].

In addition to CHF, patients exposed to anthracyclines experience other CV events including MI and stroke. In the CCSS cohort, children treated with anthracyclines developed coronary artery disease (CAD; RR 10.4, 95% CI 4.1-25.9) and cerebrovascular accidents (RR 9.3, 95% CI 4.1-21.1) more frequently than their siblings without cancer \[[@B22]-[@B26]\]. Similarly, in women over the age of 65 years treated with adjuvant anthracycline chemotherapy for Stage I or II breast cancer, MI, stroke, and other CV events were the primary cause of death in those surviving 5 years beyond initiation of their treatment \[[@B8]\].

In adults, the combination of anthracyclines and radiation therapy further increases CV events, particularly MI. In the British National Lymphoma Investigation database, a higher incidence of MI was noted in survivors of Hodgkin's disease who received radiation therapy and anthracycline-based chemotherapy \[[@B27]\]. The RR of death due to MI after radiation therapy ranged from 1.6 to 9.5 depending on radiation type and the associated chemotherapy regimen utilized in the treatment plan \[[@B27]\]. Furthermore, the RR of death due to MI was 4.1 in the first year after treatment and remained elevated at 2.5 for more than 25 years after treatment.

Similar late risks of cardiac death were noted in 1,080 patients with Hodgkin's lymphoma aged ≤50 years. In these patients, radiation and chemotherapy were associated with cardiac mortality (RR 3.2 \[1.9-5.2\]) that remained elevated (RR 4.5 \[1.2-11.6\]) 20 years after treatment \[[@B28]\]. Overall, as described by Yeh et al., the cumulative dose of anthracycline, the concomitant administration of other cardio-toxic agents, prior radiation therapy, female gender, increasing age, or the presence of diabetes or hypertension are risk factors for developing cardiovascular injury upon receipt of anthracycline based chemotherapy with or without radiation therapy \[[@B29]-[@B33]\].

### Tyrosine kinase inhibitors - trastuzumab

Tyrosine kinases modulate cellular growth, differentiation and metabolism \[[@B34]\]. Inhibitors of tyrosine kinases have been associated with down regulation of many cancer cell related functions \[[@B35]\]. In general, these agents are of two broad types: monoclonal antibodies, such as trastuzumab and bevacizumab, and small molecule inhibitors, such as lapatinib, imatinib, sorafenib, and sunitinib. Over the past 5 to 10 years, it has been recognized that many of these agents are also associated with several adverse CV related abnormalities including microvascular injury, hypertension, and LV dysfunction \[[@B35],[@B36]\]. The administration of the tyrosine kinase inhibitor trastuzumab to women with HER2-positive breast cancer has been associated with subclinical deteriorations in left ventricular ejection fraction (LVEF) \[[@B36]\]. Piccart-Gebhart, et al. identified the incidence of clinical CHF or a subclinical deterioration of LVEF, defined as a decrease in LVEF by 10% \[[@B37]\], to be 1.7% and 7%, respectively, in women receiving trastuzumab. In a separate study by Seidman, et al. cardiac dysfunction, defined as symptomatic CHF or an asymptomatic deterioration in LVEF of 10%, occurred in 27% of women who received trastuzumab versus 8% receiving an anthracycline/cyclophosphamide combination \[[@B16]\]. Cardiac dysfunction with trastuzumab has been previously reported to occur in 13% of women as opposed to only 1% of women who received paclitaxel without trastuzumab \[[@B16]\].

Anthracycline cardiotoxicity appears to be potentiated by the concomitant administration of trastuzumab. This particular combination is associated with the development of severe LV systolic dysfunction, and as a result, these agents are now administered in series (as opposed to simultaneously) when utilized to treat breast cancer. Furthermore, some trials have shown that increasing the duration between anthracycline and trastuzumab administration reduces the incidence of LV dysfunction during treatment for breast cancer \[[@B16],[@B38]\].

### Hormone deprivation therapies

In women with breast cancer or men with prostate cancer, the application of hormone deprivation therapies (aromatase inhibitors for post-menopausal women and gonadotropin releasing hormone \[GnRH\] agonists, anti-androgens, or orchiectomy in men) have dramatically improved cancer-related survival and reduced cancer-related recurrence \[[@B39]-[@B42]\]. Importantly however, it is increasingly recognized that these therapies are associated with CV events \[[@B43],[@B44]\]. Androgen deprivation therapy (ADT) is associated with the development of peripheral arterial disease (PAD) and cerebrovascular disease including stroke or transient ischemic attack (TIA) \[[@B45]\]. Among 182,757 men \>66 years in age, ADT was associated with a 5-year increased incidence of PAD upon receipt of GnRH agonists (adjusted HR 1.16, 95% CI 1.12--1.21) or after bilateral orchiectomy (adjusted HR 1.13, 95% CI 1.02--1.26) \[[@B45]\]. Both therapeutic strategies were associated with an increase in venous thromboembolism (adjusted HR 1.10, 95% CI 1.04--1.15; and adjusted HR 1.27, 95% CI 1.11--1.45, respectively) \[[@B45]\]. Prior studies have reported that PAD develops shortly (as early as 1 to 4 months) after ADT initiation and is often accompanied by an increase in incident diabetes and serum lipoprotein abnormalities.

Multiple studies have confirmed an increased risk of stroke/TIA after receipt of GnRH agonists, oral anti-androgens or bilateral orchiectomy \[[@B46],[@B47]\]. Among 22,310 men with prostate cancer followed for an average of 3.9 years, ADT use was associated with the development of stroke/TIA, specifically GnRH agonists (adjusted RR 1.18, 95% CI 1.00--1.39), oral anti-androgens (adjusted RR 1.47, 95% CI 1.08--2.01), and those who underwent bilateral orchiectomy (adjusted RR 1.77, 95% CI 1.25-- 2.39) \[[@B48]\]. The risk was not modified based on the presence of underlying cardiac risk factors with the highest risk seen in men \<65 years of age (adjusted HR 2.47, 95% CI 1.24-4.47).

In post-menopausal women, the administration of aromatase inhibitors reduces breast cancer recurrence \[[@B42],[@B49]\]. The etiology of this reduction is felt to be related to the severe reduction in circulating estrogens to near unmeasurable levels \[[@B40]\]. It is becoming increasingly recognized, however, that vascular disease and associated CV events are becoming more prevalent upon receipt of aromatase inhibitors. In a meta-analysis of seven trials that included 30,023 patients comparing aromatase inhibitors and tamoxifen, longer durations of aromatase inhibitor use was associated with increases in the odds ratios of developing CV disease (OR 1.26, 95% CI 1.10-1.43, p \< 0.001) \[[@B39]\].

In summary, for some individuals, traditional and newer therapeutic interventions for cancer (Table [1](#T1){ref-type="table"}) can promote a variety of both cardiac (CHF) and vascular (MI, stroke, PAD) associated disorders. With the emergence of these disorders affecting multiple components of the CV system, there exists a unique opportunity to utilize imaging to both diagnose and guide therapeutic interventions to diagnose and then guide the administration of therapeutic interventions to prevent these untoward effects.

Identification of cardiac toxicity
----------------------------------

For the heart, several strategies have been utilized to identify myocardial injury related to the administration for cancer \[[@B50]\]. Upon the first recognition of anthracycline-related myocardial dysfunction, endomyocardial biopsies were performed to identify histopathologic evidence of myofibrillar loss, vacuolization and extracellular loss \[[@B51],[@B52]\] and thereby confirm or refute the presence of cardiotoxicity. Importantly however, this form of monitoring became impractical for widespread clinical application as the technique required an invasive procedure that was not well-suited for repetitive examinations \[[@B50]\].

In the 1970s and 1980s, serial multigated nuclear radioisotope studies or MUGA exams were serially implemented to detect LV systolic dysfunction in patients treated with anthracycline-based chemotherapy \[[@B53],[@B54]\]. Evidence of deterioration in LVEF on MUGA scans during receipt of anthracycline chemotherapy was associated with the development of CHF \[[@B53],[@B55]\]. Today, many of the existing management protocols rely on serial measures of LVEF by MUGA or transthoracic echocardiography to identify chemotherapy or immunotherapy induced reductions in LV ejection fraction \[[@B56],[@B57]\]. Importantly however, distinguishing relatively small changes in LVEF related to cardiotoxicity from those related to variance in the technique can be problematic. As a result, more advanced transthoracic echocardiography (strain or diastolic function) assessments, \[[@B58]\] with or without concomitant serum biomarkers (such as serum troponin I levels \[[@B59],[@B60]\]) have been utilized with a goal of increasing detection of early evidence of cardiac injury after chemotherapy \[[@B61],[@B62]\]. The goal of these strategies is to identify those at risk of future CV events in order to implement therapy to prevent these events.

It is important to note, however, that difficulties remain with some of these newer quantitative strategies. Echocardiography can be difficult to reliably perform longitudinally over time due to body habitus, prior radiation treatment, or prosthetic implants, and therefore, it can be difficult to obtain adequate images from reproducible slice positions in a reliable fashion. While serum biomarkers can be easily acquired, these tests can lack specificity for cardiac injury related to the administration of therapy for cancer. Reduced specificity of identification of chemotherapy-related cardiac injury can lead to the unnecessary premature termination of chemotherapy that prevents an individual cancer patient from realizing the full benefit of his or her medical regimen.

Uniquely, CMR is well-suited to impact the detection of CV injury after receipt of cancer treatment. CMR does not incorporate ionizing radiation, thus is useful for repetitive evaluations \[[@B63]\]. During a single exam, both the heart and vasculature can be simultaneously assessed, an important feature when evaluating patients receiving multiple therapies that can promote injury to multiple components of the CV system, such as cardiomyocytes and arterial endothelial cells that can both experience mitochondrial dysfunction after the administration of anthracycline chemotherapy \[[@B64],[@B65]\]. In addition, CMR can be utilized to detect multiple aspects of a disease process by characterizing tissue \[[@B66]\], measuring function \[[@B67]\], and identifying structural or metabolic abnormalities \[[@B58]\] that can be impacted by the treatment of cancer.

CMR to detect CV related injury
-------------------------------

The role of CMR in identifying cardiotoxicity can be divided into 5 broad categories (Figure [1](#F1){ref-type="fig"}A and B):

\(1\) The detection of cardiac anatomic or structural abnormalities including valvular lesions, pericardial disease, or evidence of metastasis;

\(2\) The identification and surveillance of myocellular injury;

\(3\) The surveillance of ventricular function;

\(4\) The assessment of vascular injury; and

\(5\) The evaluation of skeletal muscle injury.

![**Cardiac toxicity by type of structure affected, along with causative cancer therapies is listed below.** Valvular, pericardial and myocardial disease is shown in **A**, while vascular injury pertaining to the coronary, peripheral and aortic circulation is shown in **B**. Sample cases with a brief description of the images and the specific techniques used are shown.](1532-429X-15-66-1){#F1}

We discuss these categories in more detail in the sections below.

### Valvular and pericardial disease

In addition to cardiomyopathy and development of CAD, valvular and pericardial involvement has also been identified as progressive complications occurring late (i.e. 15--20 years) after exposure to chemotherapy and radiation therapy \[[@B68]\]. Schellong, et al. have shown that in 1,132 survivors of Hodgkin's disease who received anthracycline and radiation before 18 years of age, valvular defects were diagnosed most frequently, followed by CAD, cardiomyopathies, conduction disorders, and pericardial abnormalities with median interval between therapy and onset of cardiac disease at 20 years. At 25 years post chemotherapy and radiation therapy, the cumulative incidence of cardiac disease was 0.14, valvular disease was 0.09 and pericardial disease was 0.05 \[[@B69]\]. Aortic regurgitation was the most common abnormality identified in this cohort. Using echocardiography, in 116 patients, Wethal, et al. have identified 33% progression of aortic regurgitation (defined as new onset of aortic regurgitation on follow-up, or increase by one grade of severity) and 39% development of aortic stenosis over 12 years in young survivors (median age 22 years) of Hodgkin's lymphoma exposed to anthracyclines or radiation therapy. In a similar study of 1,249 survivors of Hodgkin's lymphoma, absolute excess risks of requiring valve replacement or pericardiectomy/pericardiocentesis were 14.1 and 4.7 per 10,000 person-years, respectively. Extremes of age (the very old and the very young) as well as male gender were predictors for these cardiac events \[[@B70]\].

### Cardiac and pericardiac metastases

In addition to detection of valvular or pericardial anatomic abnormalities, CMR is useful in detecting tumor metastasis. While primary tumors involving the heart are relatively rare \[[@B71]\], metastatic involvement is not uncommon \[[@B65]\]. Metastases can occur through direct invasion, lymphatic or hematogenous spread, or transvenous extension \[[@B71]\]. Metastases to the heart and pericardium are identified at autopsy in 10%--12% of all patients with malignancies \[[@B71],[@B72]\]. The most common cardiac manifestation is development of a pericardial effusion which occurs through direct invasion or lymphatic spread. Due to proximity, lung cancer is a common etiology of metastases to the heart and pericardium. In addition, breast tumors, malignant melanoma, renal cell carcinoma, mediastinal lymphomas, and leukemias can metastasize to the heart. While these are initially identified by echocardiography, CMR offers volumetric coverage of the entire heart and provides the necessary means to characterize the abnormal metastatic tissue through the use of cine imaging (see Additional file [1](#S1){ref-type="supplementary-material"}), T2 and T1 mapping, gadolinium enhanced perfusion, and late gadolinium enhancement as shown in Figure [2](#F2){ref-type="fig"}. These techniques facilitate the differentiation of a malignant tumor in comparison to a lipoma, thrombus or pericardial cyst.

![**Imaging of cardiac metastases.** Images from a patient with lung cancer with pericardial metastases. Panel **A** shows an axial slice of the heart acquired by steady-state free precession imaging. The red arrows point to the circumferential pericardial mass, which is hypointense and encases the entire right atrium, right ventricle and left ventricle. Panel **B** shows a cine image of the pericardial mass in a short-axis orientation (an additional movie file shows the cine series in motion \[see Additional file [1](#S1){ref-type="supplementary-material"}\]). In addition to the circumferential extent of the mass, the anterolateral wall of the left ventricle and the free wall of the right ventricle are tethered to the mass with reduced wall thickening and motion (arrows). Panel **C** shows a T2 weighted image in the same short-axis orientation. The red arrows point to the hyperintense mass. Panel **D** shows a delayed enhancement image of the mass in the short axis orientation. The red arrow points to the areas of hyperenhancement within the mass. The blue arrow points to the necrotic areas within the mass which are hypoenhanced with low signal intensity.](1532-429X-15-66-2){#F2}

### Myocellular injury

Of all the chemotherapeutic agents, anthracyclines have been the most extensively studied in terms of myocardial histopathologic changes in the short and long-term. As shown by Billingham and Isner, et al. \[[@B52],[@B73]\] some individuals do not, whereas others do, exhibit evidence of myocellular injury (myofibrillar loss, myocyte vacuolization, cellular necrosis and perivascular and interstitial fibrosis) after anthracycline exposure. With myocyte loss and interstitial edema, there is an expansion of the myocardial extracellular space and thereby the volume of distribution of water. This leads to the prolongation of T1 and T2 and thus increased signal intensity on T1 and T2 weighted images and signal prolongation (in msec) on T1 and T2 maps.

Evidence that changes in T1 signal could be appreciated with CMR were identified as early as 1987 when Thompson, et al. reported changes in pre-contrast T1 in a model of chronic adriamycin cardiotoxicity (Table [2](#T2){ref-type="table"}) \[[@B74]\]. These investigators identified a significant prolongation of pre-contrast T1 in an ex-vivo model of chronic adriamycin toxicity in rats. In these same animals, changes in T2 were absent. The results of this study also identified abnormalities in myocardial energy metabolism using P31 nuclear magnetic resonance \[[@B58]\]. In this chronic adriamycin toxicity model, hemodynamic stress in the form of rapid atrial pacing was administered. Decreased myocardial phosphocreatinine levels were noted after hemodynamic stress in both the adriamycin-treated and the control rats. However, the adriamycin-treated rats experienced a delay and impartial recovery of the phosphocreatinine levels compared to controls. Thus after chronic receipt of adriamycin, both T1 tissue characteristics and cellular metabolism became abnormal after stress.

###### 

Changes in Myocardial signal characteristics after cancer treatment

  **Study**                                                                 **Cancer therapy**                                      **Myocardial signal characterization**   **How assessed**                                      **Subjects (\# and type)**   **Findings**
  ------------------------------------------------------------------------- ------------------------------------------------------- ---------------------------------------- ----------------------------------------------------- ---------------------------- --------------------------------------------------------------------------------------------
  Thompson et al. \[[@B74]\]                                                Anthracycline chronic toxicity                          T1 changes, no T2 changes                Ex vivo spin echo                                     Rat model                    Prolongation of pre-contrast T1.
  Cottin et al. \[[@B75]\]                                                  Anthracycline acute toxicity, 1 week                    T1 and T2 changes                        Ex vivo inversion recovery for T1, spin echo for T2   Rat model, n = 23            Prolongation of pre-contrast T1 and T2.
  Wassmuth et al. \[[@B76]\]                                                Anthracycline acute toxicity, Day 3 and 28              T1 changes on Day 3                      Contrast enhanced Spin echo                           Humans, n = 79               Higher signal intensities on T1 weighted imaging.
  Lightfoot et al. \[[@B77]\]                                               Anthracycline, acute toxicity at 2, 4, 7 and 10 weeks   T1 changes at 2 weeks and 4 weeks        Post-contrast T1 weighted inversion recovery          Rat model, n = 40            Higher signal intensity than control rats.
  This occurred early after chemotherapy and prior to a drop in the LVEF.                                                                                                                                                                                       
                                                                                                                                                                                                                                                                This increase in signal intensity was associated with microscopic evidence of cell injury.

The observation of increased myocardial T1 on pre-contrast images was confirmed by Cottin, et al. as early as 1 week after administration of adriamycin (Table [2](#T2){ref-type="table"}) \[[@B75]\]. This group also noted an increase in myocardial water content, and dissimilar to the Thompson results, an increase in T2, localized to the lateral free wall. These abnormalities occurred prior to deterioration in LV systolic performance. This group also identified abnormalities of lipid peroxidation concomitant with the observed increase in myocardial T1 and T2 signal.

Similarly, abnormalities in signal intensity on post-contrast T1 weighted images were noticed in human studies by Wassmuth, et al. \[[@B76]\]. This group of investigators used contrast enhanced spin echo in 22 patients who were imaged at 3 and 28 days after receipt of anthracycline chemotherapy. Higher myocardial signal intensities were noted as early as 3 days after receipt of anthracycline chemotherapy and predicted a future drop in the LVEF. Furthermore, patients who did not experience contrast enhancement maintained their LVEF after receipt of anthracycline chemotherapy.

Subsequently, with the advent of inversion recovery gradient recalled echo (GRE) sequences and the ability to identify myocardial fibrosis with gadolinium contrast, a study was performed by Lightfoot, et al. with a larger number of animals to assess the changes in myocardial T1 after varying doses of the anthracycline doxorubicin (Table [2](#T2){ref-type="table"}) \[[@B77]\]. The changes in signal intensity in post-contrast T1 weighted images in 40 rats exposed to two different doses of doxorubicin (1.5 and 2.5 mg/kg/week) were measured and compared to that from animals that received saline. Animals that experienced a drop in the LVEF after receipt of low or high doses of doxorubicin demonstrated higher mean signal intensity measured in the post-gadolinium T1 weighted inversion recovery images of the LV myocardium relative to those animals whose LVEF was maintained (Figure [3](#F3){ref-type="fig"}). Furthermore, increases in signal intensity during early measurement points were 80% sensitive and 82% specific for forecasting a future drop in LVEF. As shown in Figure [3](#F3){ref-type="fig"}, animals with higher signal intensities were found to have typical microscopic evidence of myocellular injury due to myocardial vacuolization and the accumulation of intra- and extracellular edema. Animals without cardiac dysfunction exhibited normal signal intensities and no histopathologic evidence of myocellular injury (Figure [3](#F3){ref-type="fig"}).

![**Correlation of T1 signal intensity change after anthracycline exposure with histopathologic changes in the myocardium.** Serial histograms and histopathology of the myocardium before and after receipt of anthracycline. On the top portion of the figure are shown 4-week histograms of the number of pixels (y-axes) and intensities (x-axes) in individual animals after receipt of NS (top left), DOX without an EF drop (top middle), and DOX with an EF drop (top right). Below the histograms are 40× hematoxylin and eosin histopathologic images from the same animals. As shown, mean intensity increased in the animals that had a drop in EF corresponding to vacuolization (arrows, bottom right). *Reprinted from Lightfoot, et al. Circ Cardiovasc Imaging 2010*\[[@B77]\]*.*](1532-429X-15-66-3){#F3}

With myocyte loss and interstitial edema, there is an expansion of the myocardial extracellular space and hence the volume of distribution of gadolinium contrast. This enables incorporation of these T1 mapping techniques for assessment of diffuse myocardial fibrosis in routine clinical studies. While conventional delayed enhancement imaging is excellent for the detection of focal myocardial fibrosis, this requires nulling of the remaining myocardium rendering it more difficult to assess diffuse myocardial fibrosis. Multiple studies have confirmed the utility of T1 mapping before and after gadolinium to identify the myocardial partition coefficient of gadolinium and thereby the myocardial extracellular volume fraction (ECVF) \[[@B78]-[@B80]\]. Messroghli, et al. have developed accurate T1 mapping techniques to be performed in a single breathhold \[[@B81]-[@B83]\], and Flett, et al. have studied alternative T1 mapping techniques and found an excellent correlation between diffuse fibrosis and the histological collagen volume fraction in patients with myocardial hypertrophy due to aortic stenosis or hypertrophic cardiomyopathy \[[@B84]\]. In patients with cardiomyopathy, the myocardial ECVF assessment has prognostic value beyond assessment of LVEF \[[@B85]\]. Whether similar prognostic value of the myocardial ECVF can be assessed in cancer survivors is an area of ongoing study.

In summary, CMR has the potential to assess early cardiac injury by using T2 mapping and pre- and post-contrast T1 mapping. This ability to identify myocardial abnormalities that precede functional impairment offers an opportunity to study the benefit of starting cardioprotective agents before overt functional deterioration.

### Ventricular function

With the realization that evidence of myocardial injury due to the administration of anthracyclines could be appreciated during invasive endomyocardial biopsies or from diagnostic catheterization procedures, investigators sought to develop non-invasive methodologies to accomplish early detection of chemotherapy-related myocardial injury. In 1979, Alexander, et al. utilized quantitative, multi-gated radionuclide angiocardiography (or MUGA) scanning to serially assess LVEF in patients scheduled to receive doxorubicin for treatment of cancer. In a cohort of 55 individuals, a decline in LVEF by at least 15% to a final value of \<45% was associated with the development of CHF in patients receiving \>350 mg/m^2^ of anthracycline chemotherapy \[[@B53],[@B86]\]. Soon thereafter, other investigators confirmed these findings \[[@B57]\].

As a result of these and other early non-invasive imaging studies, guidelines were published in 1992 that highlighted the use of LVEF measurements to screen and monitor patients for the development of cardiotoxicity and chemotherapy associated CHF \[[@B57],[@B86]\]. These guidelines included an assessment of baseline LVEF prior to chemotherapy followed by subsequent LVEF measurements depending on the frequency and cumulative anthracycline dose prescribed. During serial surveillance, if a patient developed a deterioration in LVEF, then the risk of developing CHF was elevated and therapeutic interventions were suggested. It was also recognized that the surveillance strategy could be modified due to the presence of potential additional risk factors for anthracycline-based myocardial injury. These risk factors included the application of mediastinal radiation, age (the very young and those with advanced age), pre-existing heart disease, and the associated administration of cyclophosphamide. Today, the majority of these early established guidelines are pervasive in the application of clinical care for patients that will receive anthracycline-based chemotherapy for the treatment of cancer.

Recent trials of newer cancer therapies that also promote cardiac injury such as trastuzumab, also routinely monitor LVEF with echocardiography or MUGA scanning to detect early deteriorations in LVEF that predispose one to develop CHF \[[@B36]\]. Guidelines have been published for the surveillance of LVEF during trastuzumab or other cancer therapies by the UK National Cancer Institute \[[@B87]\], and by the European Society of Medical Oncology \[[@B88]\]. In addition to baseline assessments of LVEF, additional assessments are recommended at 3, 6, and 9 months after treatment with anthracyclines, and at 4 monthly intervals for trastuzumab. Furthermore, the UK National Cancer Institute guidelines detail the use of a "traffic light" system to enable detection and management of cardiotoxicity with trastuzumab in which the therapeutic administration of angiotensin converting enzyme inhibitors is directed through measurement of LVEF.

CMR is well-suited to assess LVEF prior to and during receipt of potentially cardiotoxic chemotherapy. The ability to acquire images in multiple tomographic planes without limitations imposed by body habitus enable CMR LVEF assessments to be performed in patients who may have undergone prior surgery to pericardiac regions including the chest, lungs and mediastinum. Importantly, CMR accurately measures the ventricular volumes that contribute to the LVEF calculation. Compared with two-dimensional (2D) echocardiography, the inter-study coefficient of variability for assessment of LV volumes, function and mass was superior for CMR among healthy individuals, as well as those with heart failure or left ventricular hypertrophy \[[@B89]\]. The inter-study reproducibility for CMR measured end-systolic volume was 4.4% to 9.2% (versus 12.7 to 20.3% for 2D echocardiography), for ejection fraction was 2.4% to 7.3% (versus 8.6% to 9.4% for 2D echocardiography), and for LV mass was 2.8% to 4.8% (versus 11.6% to 15.7% for 2D echocardiography) \[[@B89]\]. Similarly, low inter-observer variability was noted in a comprehensive study comparing CMR volumes derived by cine and spin echo CMR \[[@B90]\]. Abnormalities of left ventricular end-diastolic volume (LVEDV), which could be due to changes in LV pre-load, can be detected with CMR. This LVEDV assessment is particularly important in patients receiving treatment for cancer who may exhibit altered pre-load due to poor oral intake or excessive nausea and vomiting. In addition, CMR can accurately identify abnormalities of left ventricular end-systolic volume (LVESV), which reflect abnormalities of myocardial contractility. Finally, the 3-dimensional acquisitions of these LV volumes and EF are very useful when cardiac function becomes reduced and the left ventricle assumes an abnormal shape that may differ from a prolate ellipsoid that is often assumed for the calculation of LVEF using a 2D technique.

In addition to determinations of LV volumes and EF, other measures of LV systolic and diastolic function can be obtained during the same CMR examination. For example, myocardial strain, a unitless measure of myocardial deformation can be assessed during ventricular systole or during ventricular diastole (strain rate). Both of these measures may provide incremental diagnostic information relative to LV function \[[@B91]\]. These values have been useful in assessing and identifying individuals with abnormalities of LV function due to ischemic \[[@B92]\] and non-ischemic cardiomyopathies \[[@B93]\] as well as other infiltrative myocardial diseases such as systemic amyloidosis \[[@B94],[@B95]\]. Recently, Drafts, et al. acquired serial assessments of LV volumes and myocardial strain to identify abnormalities of LV performance during receipt of anthracycline chemotherapy. In 55 individuals scheduled to receive an anthracycline-based chemotherapeutic regimen for leukemia, lymphoma, or breast cancer, Drafts, et al., found that measures of LV systolic performance (LVESV and myocardial strain) deteriorated early (even after the first dose) of the administration of anthracycline-based chemotherapy (Figure [4](#F4){ref-type="fig"}) \[[@B96]\]. Moreover, these deteriorations remained present after the discontinuation of anthracycline chemotherapy. These data highlight the potential utility of CMR for identifying abnormalities of LV performance that indicate ongoing cardiac dysfunction due to toxicity from anthracycline-based regimens. Combining both these advanced functional measures with myocardial tissue characterization techniques (such as the mapping technologies mentioned previously) could provide a new strategy for identifying those at risk of CHF and thereby guide therapeutic interventions to reduce these risks. Currently, a large multi-center randomized trial is underway utilizing CMR to assess the efficacy of conventional heart failure drugs such as ACEIs and beta-blockers in patients receiving trastuzumab therapy for breast cancer \[[@B97]\].

![**Serial changes in LV volumes, myocardial strain and LVEF after anthracycline exposure in human subjects.** Time dependent changes in left ventricular (LV) end diastolic volume (left y-axis; panel **A**) and LV end systolic volume (right y-axis; panel **A**); in LV ejection fraction (left y-axis; panel **B**); serum Troponin-I (right y-axis; panel **B**); pulse wave velocity (PWV) (left y-axis; panel **C**); and mean mid wall circumferential strain (right y-axis; panel **C**). The mean ± the standard error are shown. There was a substantive increase in LV end systolic volume, PWV, and serum Troponin-I while at the same time a decrease in LV ejection fraction and mean mid-wall circumferential strain from baseline to six months after administration of low to moderate doses of anthracycline-based chemotherapy. *Reprinted from Drafts, et al. JACC-Imaging 2012*\[[@B96]\]*.*](1532-429X-15-66-4){#F4}

In addition to myocardial strain and volume assessment, promising techniques being developed include diffusion tensor imaging for the identification of impaired myocardial mechanics, \[[@B98]\] for example, impaired torsion and spectroscopy for assessing abnormal myocardial metabolism \[[@B99]\]. These techniques are currently being studied in hypertrophic cardiomyopathy and could be potentially used in patients exposed to cancer therapies, to identify myocardial abnormalities prior to the onset of overt systolic dysfunction.

### Vascular injury

It is important to recognize that in addition to the development of CHF, many treatments for cancer also predispose individuals to the development of CV events related to abnormalities of the vascular system. These CV events include the development of MI, PAD, and stroke. Several different cancer therapies have been shown to promote these vascular related events.

Hormonal therapy such as ADT is associated with an increased incidence of MI, PAD, and stroke \[[@B45],[@B46],[@B100]\]. Tyrosine kinase inhibitors such as bevacizumab, sorafinib and sunitinib promote hypertension \[[@B100]-[@B103]\]. Recently, Chaosuwannakit, et al. demonstrated that proximal aortic wall stiffness increased 3 months after receipt of anthracycline-based chemotherapy compared to age matched controls (Figure [5](#F5){ref-type="fig"}) \[[@B64]\]. Among the anthracycline-based chemotherapy recipients, the increased aortic stiffness was noted even after controlling for factors such as age, gender, diabetes, hyperlipidemia and hypertension. The magnitude of the increase was equivalent to that associated with aging the CV system by 10--20 years.

![**Serial changes in aortic stiffness in chemotherapy recipients.** Chaosuwannakit, et al. demonstrated that pulse wave velocity (PWV) increased in participants receiving cancer therapy. PWV results for the control participants **(A)** and the participants receiving cancer therapy **(B)**. The increase in PWV observed in this study is associated with a 3-fold increase in the risk of a future CV event and consistent with a 10 to 20 year age associated increment of the cardiovascular system. *Reprinted from Chaosuwannakit, et al. J Clin Oncol 2010*\[[@B64]\]*.*](1532-429X-15-66-5){#F5}

Two additional features of this increase in stiffness are noteworthy. First, this occurred soon after administration of chemotherapy and therefore is dissimilar to the more chronic causes of stiffening (e.g. atherosclerosis) more commonly observed. Recently, Eckman, et al. identified early histopathologic evidence of coronary artery microcirculatory endothelial damage in an animal model of anthracycline cardiotoxicity \[[@B104]\]. Perhaps endothelial damage to the vasa vasorum supply or on the luminal surface of the aorta contributed to the abrupt increase in aortic stiffening. Further research is needed in this area.

Second, the increases in aortic stiffening were not dose dependent. This finding suggests there may be thresholds of susceptibility to vascular dysfunction, and further research may be useful in identifying these susceptibilities. These increases in aortic stiffness could have important clinical ramifications. Abnormal increases in proximal aortic stiffness have been associated with LV hypertrophy, exercise capacity (particular in the elderly) \[[@B105]\], and future CV events in those with diabetes, hypertension, renal failure, and advanced age. It is important to note, however, that it is unknown whether these increases in aortic stiffness are transient or whether they reverse after changes in therapy.

Additional changes to the vascular system have been reported upon receipt of treatment for cancer. These include the development of accelerated atherosclerosis and abnormalities of peripheral arterial endothelial function. In men treated for prostate cancer and post-menopausal women treated for breast cancer, the administration of ADT men and estrogen deprivation for women have been associated with the development of metabolic syndrome, diabetes, atherosclerosis, and CV events. Although not studied previously, there is potential for CMR to be used to identify the rapid progression of atherosclerosis by identifying abnormalities of aortic or carotid arterial wall thickness or the components of plaque composition (Figure [1](#F1){ref-type="fig"}B).

The administration of anthracycline-based chemotherapy has been associated with abnormalities of peripheral arterial and endothelial function. Endothelial function can be assessed noninvasively through the assessment of flow mediated arterial dilation (FMAD). CMR is highly advantageous for the assessment of peripheral arterial FMAD (Figure [1](#F1){ref-type="fig"}B). Phase contrast techniques that measure both wall shear stress and arterial dilation can be performed prior to, during, and after cuff inflation on both the upper as well as the lower extremity. These measures have been useful in identifying abnormalities of FMAD in older individuals with heart failure due to a reduced or preserved LVEF. At present, CMR FMAD measurements have not been acquired in patients treated for cancer. As the number of therapies targeted toward the vascular supply of tumors increases, the proven utility of CMR for assessing peripheral arterial endothelial function may be useful for identifying unintended injury to the native arterial circulation.

### Skeletal muscle function as a contributor to exercise capacity and fatigue

Fatigue and muscle weakness are common among recipients of chemotherapy, and often they persist for many years after cessation of cancer treatment \[[@B106]-[@B108]\]. Perceived fatigue and weakness is debilitating with a profoundly negative impact on quality of life. In 33% of women surviving treatment for breast cancer, fatigue is progressive and severely limits the ability to return to work \[[@B106]\]. In addition, fatigue may influence exercise capacity, a known predictor of CV events. Patients who received chemotherapy experience both fatigue and exercise intolerance, and therapeutic interventions that modify exercise capacity in cancer survivors also improve fatigue \[[@B109]\]. In fact, physical activity \>3 METS is associated with reduced CV related morbidity and mortality in survivors of both breast and colon cancer \[[@B110],[@B111]\].

In those capable of normal ambulation, exercise capacity is influenced during stress by changes in cardiac output, arterial and microcirculatory function, and skeletal muscle metabolism and function. CMR is well-suited to assess all three of these components of exercise capacity both at rest and during pharmacologic or exercise induced stress. In elderly patients with heart failure and preserved or reduced EF \[[@B112],[@B113]\], CMR derived information from these three components has been utilized to understand mechanisms of disability and exercise intolerance.

In addition to the cancer therapy mediated cardiac and vascular abnormalities identified in Table [1](#T1){ref-type="table"}, skeletal muscle dysfunction may also occur after treatment for cancer. For example, doxorubicin potentiates direct skeletal muscle weakness through generation of reactive oxygen species and TNFα signaling \[[@B114]\]. Anthracyclines accumulate in skeletal muscle and have been shown to decrease muscle force on direct muscle force testing \[[@B115]\]. In addition they also cause loss of myofibrillar organization and interstitial edema \[[@B116]\]. To date, the role of the skeletal muscle weakness in exercise intolerance in chemotherapy recipients has not been systematically addressed; however, skeletal muscle energetics assessed at rest or after exercise with multi-nuclear spectroscopy could be highly informative in detecting abnormalities of ATP utilization that occur as a result of the impact of oxidative stress on the working mitochondria (Figure [1](#F1){ref-type="fig"}A). In addition, skeletal muscle oxygen uptake can be studied with novel blood oxygen level dependent (BOLD) MRI techniques. BOLD signaling relies on the hemoglobin oxygen saturation \[[@B117]\]. During increased tissue perfusion at constant levels of oxygen extraction, the oxyhemoglobin concentration is higher, and a lower concentration of paramagnetic deoxyhemoglobin is noted. This results in an increase in the T2 and T2\* signal (positive BOLD signal). Coupling these BOLD assessments with measurements of skeletal muscle level microcirculatory perfusion after exercise using arterial spin labeling would be helpful to delineate muscle oxygen extraction for given levels of perfusion. In the calf of individuals with PAD, skeletal muscle phosphocreatine recovery after exercise has been shown to be diminished relative to control populations \[[@B118]\], and in combination with the measures of perfusion, oxygen utilization, and skeletal muscle mass, the incorporation of energetics could provide a more complete and quite novel understanding of the etiology of fatigue in cancer survivors (Figure [1](#F1){ref-type="fig"}A and B).

Future directions:

We have identified areas of research in cardiovascular toxicity beyond the assessment of cardiac structure and function, specifically to explore the mechanisms leading to co-morbidities that have a delayed onset after the initial exposure to cancer therapeutics. Table [3](#T3){ref-type="table"} provides a list of available newer MRI tools that can be utilized to assess the etiology of fatigue, accelerated atherosclerosis of the coronary, cerebral and peripheral vascular systems in addition to accelerated stiffness of the entire vascular system.

###### 

Unresolved issues in cancer survivors and possible techniques to address these issues

  **Morbidity**                                               **Unresolved question**                                         **Proposed MRI technique**
  ----------------------------------------------------------- --------------------------------------------------------------- -----------------------------------------------------------------------------
  Cerebro vascular accident                                   Accelerated atherosclerosis                                     Wall thickness of ascending, descending aorta, plaque characterization
  Myocardial infarction                                       Coronary flow reserve using quantitative myocardial perfusion   
  Peripheral vascular disease                                 Wall thickness of femoral arteries, BOLD imaging                
  LV systolic dysfunction                                     Early detection of myocellular injury and risk stratification   T1, T2 and ECV mapping
  Strain imaging                                                                                                              
  Impairment of myocardial mechanics, i.e. Impaired torsion   Diffusion tensor imaging                                        
  Myocardial energy metabolism                                NMR P32 spectroscopy                                            
  Impaired exercise tolerance                                 Arterial stiffness                                              4D Flow for assessing pulse wave velocity
  Fatigue                                                     Skeletal muscle injury                                          NMR spectroscopy to assess for mitochondrial dysfunction in skeletal muscle
  Fat/water separation to assess fat content                                                                                  
  Hypertension                                                Endothelial dysfunction                                         Flow mediated arterial dilation

Conclusion
==========

In summary, although cancer free survival is improving for many individuals treated for malignancies, an unintended consequence has been the emergence of cardiovascular events in the form of heart failure, myocardial infarction, stroke, and peripheral arterial disease. Temporally, it appears that these cardiovascular events and underlying subclinical cardiovascular disease are related to the therapies received for cancer. To this end, the ability of cardiovascular magnetic resonance to characterize and assess the function of the cardiovascular system is useful in identifying subclinical abnormalities of cardiovascular function that often precede CV events. Several single center studies have demonstrated the utility of CMR technologies to identify this early subclinical cardiovascular injury. Importantly however, further research is needed to fully develop cardiovascular magnetic procedures that both diagnose and also guide therapeutic interventions to prevent cardiovascular event and also the pronounced fatigue and related morbidities associated with administration of therapy for cancer.
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**Pericardial mass cineseries.** Advanced Systems Format File (.asf) showing cine image of the pericardial mass in a short-axis orientation.
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